Silexion Therapeutics to Attend BIO International Convention 2026

Rhea-AI Summary

Silexion Therapeutics (NASDAQ:SLXN), a clinical-stage biotech developing RNAi therapies for KRAS-driven cancers, will attend the 2026 BIO International Convention in San Diego, CA from June 22–25, 2026.

Company leadership will host one-on-one investor and partner meetings during the convention.

News Market Reaction – SLXN

+7.01%

13 alerts

+7.01% Session close to close

+3.0% Peak Tracked

-19.7% Trough Tracked

$1.25M Market Cap

0.1x Rel. Volume

In the Jun 17 session, SLXN gained 7.01%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.0% during that session. Argus tracked a trough of -19.7% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +7.0% in the session following this news. A strong positive reaction aligns with a m...

Analysis

The stock moved +7.0% in the session following this news. A strong positive reaction aligns with a market occasionally rewarding non-dilutive, visibility-enhancing updates, even when fundamentals show prior pressure. SLXN recently traded at $2.71, far below its 200-day MA of $22.32 and 98.79% under its 52-week high, after several capital-structure and financing steps. Investors would have weighed this BIO convention appearance alongside existing warrant overhang and an effective resale registration allowing up to $4.9 million in potential warrant-exercise proceeds.

Key Figures

Convention year: 2026 Convention dates: June 22–25, 2026

2 metrics

Convention year 2026 BIO International Convention 2026 attendance

Convention dates June 22–25, 2026 BIO International Convention in San Diego, CA

Historical Context

5 past events · Latest: May 26 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 26	Reverse share split	Negative	-14.1%	1-for-10 reverse split to support Nasdaq bid-price and capital structure.
May 18	Earnings and update	Negative	-5.4%	Q1 2026 results with higher R&D, larger net loss, lower cash and equity focus.
May 15	Warrant exercise financing	Negative	-42.1%	Immediate cash exercise of warrants and issuance of new Series C/D warrants.
May 14	Preclinical efficacy data	Positive	-9.3%	Positive preclinical immuno-oncology data for SIL204 in KRAS-driven cancers.
May 13	Trial supply and approval	Positive	-5.0%	GMP batch manufacturing and new ethics approval for Phase 2/3 SIL204 trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news, including financings, clinical progress, and a reverse split, has often been followed by negative price reactions, even to seemingly positive clinical updates.

Recent Company History

Over the last month, SLXN announced GMP clinical supply and ethics approval for its SIL204 Phase 2/3 trial (May 13), positive preclinical immunotherapy findings (May 14), a warrant exercise financing with new Series C/D warrants (May 15), Q1 2026 results with higher R&D, larger net loss, and lower cash (May 18), and a 1-for-10 reverse split to maintain Nasdaq bid compliance (May 26). All five items saw negative 24h price reactions, suggesting persistent selling pressure around both clinical and capital-structure developments.

Key Terms

rna interference, rnai, kras-driven cancers

3 terms

rna interference medical

"a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for"

RNA interference is a natural cellular process that acts like a mute switch to reduce or silence the activity of a specific gene by targeting its messenger RNA, the blueprint used to make a protein. For investors, it matters because therapies and diagnostics that harness this mechanism can precisely block disease-causing proteins, creating new drug classes with high potential reward but also scientific, manufacturing and regulatory risks that affect company value.

rnai medical

"biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers"

RNAi, short for RNA interference, is a natural cellular process that acts like a mute button for specific genes by using small RNA molecules to stop a target gene from producing its protein. For investors, RNAi matters because it is the underlying mechanism behind a class of precision medicines that can silence disease-causing genes, offering high potential returns but also scientific, regulatory and manufacturing risks unique to novel drug platforms.

kras-driven cancers medical

"RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that Company"

Cancers described as "KRAS-driven" are tumors where changes in the KRAS gene act like a stuck accelerator, sending continuous growth signals that help the cancer grow and spread. For investors, this matters because such mutations define a large, hard-to-treat patient group and create specific opportunities and risks for drug developers: successful medicines against KRAS-driven cancers can command significant market value, while failures can sharply affect company prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that Company management, including the Company’s Chief Executive Officer, Ilan Hadar, and the Company’s Chief Financial Officer, Mirit Horenshtein-Hadar, will attend the 2026 BIO International Convention, taking place on June 22-25 in San Diego, CA.  

Silexion’s management will host one-on-one meetings during the BIO Convention. Interested parties should contact Silexion company representative to arrange a meeting.

About Silexion Therapuetics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product, which showed a positive trend in comparison to the control of chemotherapy alone, and is currently advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), towards clinical trials in Israel and the European Union. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https://silexion.com

Company Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com

Investor Relations
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com

Chuck Padala 
LifeSci Advisors 
Chuck@lifesciadvisors.com

FAQ

When will Silexion Therapeutics (SLXN) attend the BIO International Convention 2026?

Silexion Therapeutics will attend the BIO International Convention 2026 from June 22–25 in San Diego, CA. According to Silexion, company management, including the CEO and CFO, will be present and available for scheduled one-on-one meetings during the event.

Who from Silexion Therapeutics (SLXN) will represent the company at BIO International Convention 2026?

According to Silexion, company management attending BIO 2026 will include Chief Executive Officer Ilan Hadar and Chief Financial Officer Mirit Horenshtein-Hadar. They will participate in one-on-one meetings throughout the convention in San Diego, California, from June 22–25, 2026.

What does Silexion Therapeutics (SLXN) focus on as a clinical-stage biotechnology company?

Silexion Therapeutics is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers. According to Silexion, this oncology focus underpins its participation in BIO International Convention 2026 and its outreach to potential partners and investors at the event.

How can investors or partners schedule one-on-one meetings with Silexion Therapeutics (SLXN) at BIO 2026?

Interested parties can arrange one-on-one meetings with Silexion during BIO 2026 by contacting a Silexion company representative. According to Silexion, management will host these meetings throughout the June 22–25 convention in San Diego, California, subject to availability.

Why is Silexion Therapeutics (SLXN) attending the BIO International Convention 2026?

Silexion Therapeutics is attending BIO 2026 to engage in one-on-one meetings with interested parties. According to Silexion, its leadership team will be on-site in San Diego to discuss its RNAi pipeline for KRAS-driven cancers and explore collaboration or investment discussions.